Comparison of Dorzolamide/Timolol Versus Brimonidine/Timolol Fixed Combination Therapy in the Management of Steroid-Induced Ocular Hypertension

Seymenoğlu, Göktuğ; Başer, Esin; Kaya, Metin; Gülhan, Ceren

doi:10.1097/ijg.0b013e31829d9b5c

Cited by 6 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their conclusion was that the safety and daytime efficacy of these two FCs were comparable when employed in patients with OAG or OHT. However, in patients with steroid glaucoma BmTFC may obtain a greater hypotensive effect than DTFC [90]. This finding suggests that the effect on the trabecular meshwork of topically applied adrenergic agents may be beneficial in steroid glaucoma.…”

Section: Dtfc Therapy Employed In the Real Worldmentioning

confidence: 93%

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

et al. 2020

View full text Add to dashboard Cite

The key clinical attributes of preserved dorzolamide/timolol fixed combination (DTFC) and the emerging potential of preservative-free (PF) DTFC are reviewed with published evidence and clinical experience. The indications and role of DTFC in current glaucoma management are critically discussed. Preserved DTFC became the first intraocular pressure (IOP)-lowering fixed combination (FC) approved by the US Food and Drug Administration (FDA) and remains one of most commonly used medications worldwide. The pharmacological properties of DTFC reflect those of its two time-tested constituents, i.e., the carbonic anhydrase inhibitor dorzolamide and the non-selective beta-blocker timolol. In

show abstract

Section: Dtfc Therapy Employed In the Real Worldmentioning

confidence: 93%

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Multiple clinical trials reported that BrT-FC is better than DzT-FC in reducing IOP, although no statistically significant difference is found ( Gulkilik et al, 2011 ; Feke et al, 2013 ; Seymenoglu et al, 2015 ). The side-effect profile of BrT-FC is similar to that of DzT-FC.…”

Section: Topical Fixed Combination Of Two Agentsmentioning

confidence: 94%

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Wang

Cao²,

Jiang³

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Glaucoma is one of the most common causes of blindness, thus seriously affecting people’s health and quality of life. The topical medical therapy is as the first line treatment in the management of glaucoma since it is inexpensive, convenient, effective, and safe. This review summarizes and compares extensive clinical trials on the topical medications for the treatment of glaucoma, including topical monotherapy agents, topical fixed-combination agents, topical non-fixed combination agents, and their composition, mechanism of action, efficacy, and adverse effects, which will provide reference for optimal choice of clinical medication. Fixed-combination therapeutics offer greater efficacy, reliable security, clinical compliance, and tolerance than non-fixed combination agents and monotherapy agents, which will become a prefer option for the treatment of glaucoma. Meanwhile, we also discuss new trends in the field of new fixed combinations of medications, which may better control IOP and treat glaucoma.

show abstract

“…6 Brimonidine/timolol fixed-combination (BTFC) therapy has been established as an effective IOP-lowering treatment option for glaucoma, and a recent study reported an approximately two-fold higher IOP-lowering effect was achieved with this medication as compared with 0.5% timolol in normal-tension glaucoma patients. [7][8][9] However, much like generally used glaucoma ophthalmic solutions, BTFC ophthalmic solutions also contain benzalkonium chloride (BAK) as a preservative, which may cause ocular side effects such as mucous cell death, tear film instability, and lacrimation, especially in long-term users. 10 Many researchers have recently sought to further elucidate the harmful effect of preservatives, and the European Glaucoma Society now recommends preservative-free (PF) products for use by patients who have severe dry eye or ocular surface diseases.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma

Kim

Park

et al. 2021

Seminars in Ophthalmology

View full text Add to dashboard Cite

Purpose: To compare the therapeutic efficacy and safety of newly developed preservative-free (PF) brimonidine/timolol fixed-combination (BTFC) ophthalmic solutions and a preservative-containing (PC) BTFC ophthalmic solution in patients with open-angle glaucoma. Methods: This study was conducted as a multicenter, randomized, open-label, parallel-group clinical trial to evaluate the efficacy and safety of PF BTFC as compared with PC BTFC in adult patients (aged ≥ 19 years) with open-angle glaucoma (OAG) and ocular hypertension (OHT). A total of the 106 patients were enrolled, with 53 patients each randomized to the two treatment groups and included in the analysis of the safety set (SS). After a washout period, patients with an IOP below 35 mmHg at 9 a.m. were enrolled. After a full ophthalmic and glaucoma examination, a total of 106 OAG and OHT patients were randomized to the PF group or PC group. All subjects were examined 4 and 12 weeks after first administration. At each follow-up visit, IOP was measured at 9 a.m. and 11 a.m. and the efficacy, safety, and compliance were evaluated. Throughout the study, all adverse events were recorded and monitored by the investigators. Results The mean IOP changes from baseline to 12 weeks at 11:00 a.m. were −3.45 ± 2.53 mmHg in the PF group and −3.65 ± 2.76 mmHg in the PC group (p < .0001 for both). The difference in mean IOP change between the two groups was 0.20 ± 2.65 mmHg, which was not significantly different. The proportion of patients with IOP reductions of ≥ 15% and ≥ 20% and IOP at all-time points in the PF group were not significantly different when compared with in the PC group. There were no specific differences between the two groups regarding the incidence of adverse events. Conclusions PF BTFC ophthalmic solution shows a similar efficacy and safety profile to that of PC BTFC.

show abstract

Comparison of Dorzolamide/Timolol Versus Brimonidine/Timolol Fixed Combination Therapy in the Management of Steroid-Induced Ocular Hypertension

Abstract: Both FCBT and FCDT are effective in controlling IOP elevations after IVTA injections. The results of this study suggest that FCBT is superior to FCDT in reducing IOP and provides better IOP control after IVTA injections.

Cited by 6 publications

References 41 publications

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future

Topical Medication Therapy for Glaucoma and Ocular Hypertension

Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma

Contact Info

Product

Resources

About